Free CME from PeerView


Continuing Pharmacy Education (CPE) Activities

Credits: 1.0 CME / MOC / CC / NCPD / CPE / IPCE
PVI, PeerView Institute for Medical Education
Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy

Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy

Start

Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy

Media: Enduring Material
Activity Release Date: August 2, 2023
Activity Expiration Date: August 1, 2024
Time to Complete Activity: 60 minutes

Activity Description

Learn how CLL expert Jennifer Woyach, MD, employs patient treatment history, prognostic information, and other clinically relevant factors to develop comprehensive treatment plans for her patients and get up to date on the latest evidence with BTK inhibitors for CLL by participating in this video activity. Dr. Woyach will focus on enhancing your understanding of the mechanistic, selectivity, and safety differences between covalent and non-covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i), the mechanisms of intolerance and BTK resistance, and how BTKi fit into personalized treatment plans informed by the use of validated techniques such as next-generation sequencing, FISH, and karyotype testing. Learners will also be exposed to resources from the CLL Society that can be used to help educate patients on the latest therapeutic advances in customized CLL care.

Target Audience

This activity has been designed to meet the educational needs of hematologists, oncologists, hematology-oncologists, pathologists, nurses, pharmacists, and other clinicians involved in the care of patients with CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
  • Cite validated techniques, including next-generation sequencing, to identify prognostic and predictive markers such as del(17p)/TP53, BTK mutations, and minimal residual disease status to inform treatment decisions
  • Develop team-based management strategies that include patient treatment history, prognostic information, and other clinically relevant factors
  • Implement team-based strategies to educate patients on their prognosis, facilitate clinical trial enrollment, and address dosing and safety considerations when using BTKi strategies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Jennifer Woyach, MD
Professor of Internal Medicine
Division of Hematology
The Ohio State University
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Jennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.
Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Merck & Co., Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

ABPath The activity titled “Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-054-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy

Media: Enduring Material
Activity Release Date: August 2, 2023
Activity Expiration Date: August 1, 2024
Time to Complete Activity: 60 minutes

Activity Description

Learn how CLL expert Jennifer Woyach, MD, employs patient treatment history, prognostic information, and other clinically relevant factors to develop comprehensive treatment plans for her patients and get up to date on the latest evidence with BTK inhibitors for CLL by participating in this video activity. Dr. Woyach will focus on enhancing your understanding of the mechanistic, selectivity, and safety differences between covalent and non-covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i), the mechanisms of intolerance and BTK resistance, and how BTKi fit into personalized treatment plans informed by the use of validated techniques such as next-generation sequencing, FISH, and karyotype testing. Learners will also be exposed to resources from the CLL Society that can be used to help educate patients on the latest therapeutic advances in customized CLL care.

Target Audience

This activity has been designed to meet the educational needs of hematologists, oncologists, hematology-oncologists, pathologists, nurses, pharmacists, and other clinicians involved in the care of patients with CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
  • Cite validated techniques, including next-generation sequencing, to identify prognostic and predictive markers such as del(17p)/TP53, BTK mutations, and minimal residual disease status to inform treatment decisions
  • Develop team-based management strategies that include patient treatment history, prognostic information, and other clinically relevant factors
  • Implement team-based strategies to educate patients on their prognosis, facilitate clinical trial enrollment, and address dosing and safety considerations when using BTKi strategies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Jennifer Woyach, MD
Professor of Internal Medicine
Division of Hematology
The Ohio State University
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Jennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.
Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Merck & Co., Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

ABPath The activity titled “Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-054-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

August 01, 2023
Credits: 0.75 CME / MOC / NCPD / CPE / CECH
PVI, PeerView Institute for Medical Education
Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider

Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider

Start

Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider

Media: Enduring Material
Activity Release Date: June 29, 2023
Activity Expiration Date: June 28, 2024
Time to Complete Activity: 45 minutes

Activity Description

In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum.

Target Audience

This activity has been designed to meet the educational needs of healthcare professionals who treat, care for, and/or support people living with HIV.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify individual and structural factors that contribute to PLWH falling out of care
  • Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
  • Employ individualized and comprehensive plans to successfully re-engage PLWH in care

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Allison Agwu, MD, ScM, FAAP, FIDSA
Professor of Pediatrics and Internal Medicine
Division of Infectious Diseases
Program Director, Pediatric Adolescent Young Adult HIV/AIDS Program
Medical Director, Accessing Care Early (ACE) Clinic
Johns Hopkins University School of Medicine
Baltimore, Maryland

Allison Agwu, MD, ScM, FAAP, FIDSA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co., Inc.

Faculty/Planner
Nara Lee, LICSW
Social Work & Clinical Services Manager
HIV Prevention and Treatment Services
Special Immunology Services
Children’s National Hospital
Washington, DC

Nara Lee, LICSW, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
David Martin
Patient/Advocate

David Martin has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Shawnte' Spriggs
Patient/Advocate

Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-046-H02-P
Type of Activity: Knowledge

Health Education Specialists

Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/CECH Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider

Media: Enduring Material
Activity Release Date: June 29, 2023
Activity Expiration Date: June 28, 2024
Time to Complete Activity: 45 minutes

Activity Description

In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum.

Target Audience

This activity has been designed to meet the educational needs of healthcare professionals who treat, care for, and/or support people living with HIV.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify individual and structural factors that contribute to PLWH falling out of care
  • Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
  • Employ individualized and comprehensive plans to successfully re-engage PLWH in care

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Allison Agwu, MD, ScM, FAAP, FIDSA
Professor of Pediatrics and Internal Medicine
Division of Infectious Diseases
Program Director, Pediatric Adolescent Young Adult HIV/AIDS Program
Medical Director, Accessing Care Early (ACE) Clinic
Johns Hopkins University School of Medicine
Baltimore, Maryland

Allison Agwu, MD, ScM, FAAP, FIDSA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co., Inc.

Faculty/Planner
Nara Lee, LICSW
Social Work & Clinical Services Manager
HIV Prevention and Treatment Services
Special Immunology Services
Children’s National Hospital
Washington, DC

Nara Lee, LICSW, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
David Martin
Patient/Advocate

David Martin has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Shawnte' Spriggs
Patient/Advocate

Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-046-H02-P
Type of Activity: Knowledge

Health Education Specialists

Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/CECH Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

June 28, 2023
Credits: 1.0 CME / NCPD / CPE / IPCE
PVI, PeerView Institute for Medical Education
New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now

New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now

Start

New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now

Activity Description and Educational Objectives

Recent research and improved understanding of the pathogenesis of multiple sclerosis (MS) has led to the development of multiple biomarkers and imaging modalities that can improve clinicians’ ability to individualize therapy through more effective monitoring of disease progression and treatment response. The promise of eventually arriving at data-driven personalized care—coupled with the number of available and emerging therapies for MS treatment—makes it more important than ever that clinicians remain up-to-date on advances in biomarkers and imaging approaches, as well as shared decision-making strategies.

In this activity, based on a recent live symposium, MS experts cover the latest data on these new and emerging biomarkers for MS management. Using examples from their own practice, the panelists also discuss ways to incorporate these biomarker findings into individualized treatment decisions to empower patients and improve treatment outcomes.

Upon completion of this activity, participants should be better able to:

  • Describe emerging biomarkers that may play a role in evaluating MS disease activity, progression, and treatment response
  • Individualize treatment decisions for patients with MS, incorporating biomarker findings, disease status, and other patient-specific characteristics
  • Integrate team-based shared decision-making strategies to facilitate appropriate treatment selection, empower patients, and improve outcomes

Target Audience

This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/CPE/IPCE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: June 3, 2023 - July 2, 2024
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.

Chair & Moderator
Jiwon Oh, MD, PhD, FRCPC
Medical Director, Barlo Multiple Sclerosis Program
Associate Professor, Division of Neurology
St. Michael’s Hospital
University of Toronto
Staff Neurologist
Scientist
Keenan Research Centre of the Li Ka Shing Knowledge Institute
Toronto, Ontario, Canada

Jiwon Oh, MD, PhD, FRCPC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; Bristol Myers Squibb; EMD Serono Canada; F. Hoffmann-La Roche Ltd; Lilly; Novartis Pharmaceuticals Canada Inc.; and Sanofi/Genzyme Canada Inc.
Grant/Research Support from Biogen Canada Inc.; EMD Serono Canada; and F. Hoffmann-La Roche Ltd.
Speaker for Biogen Canada Inc.; Bristol Myers Squibb; EMD Serono Canada; F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Canada Inc.; and Sanofi/Genzyme Canada Inc.

Presenters
Jacci Bainbridge, PharmD, FCCP, MSCS, FAES
Professor
Departments of Clinical Pharmacy and Neurology
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado, Anschutz Medical Campus
Aurora, Colorado

Jacci Bainbridge, PharmD, FCCP, MSCS, FAES, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Novartis Pharmaceuticals Corporation.

Kathleen M. Costello, RN, MS, NP, MSCN
Chief Operating Officer
Can Do-Multiple Sclerosis
Avon, Colorado

Kathleen M. Costello, RN, MS, NP, MSCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6939-23-T.

Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-039-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now

Activity Description and Educational Objectives

Recent research and improved understanding of the pathogenesis of multiple sclerosis (MS) has led to the development of multiple biomarkers and imaging modalities that can improve clinicians’ ability to individualize therapy through more effective monitoring of disease progression and treatment response. The promise of eventually arriving at data-driven personalized care—coupled with the number of available and emerging therapies for MS treatment—makes it more important than ever that clinicians remain up-to-date on advances in biomarkers and imaging approaches, as well as shared decision-making strategies.

In this activity, based on a recent live symposium, MS experts cover the latest data on these new and emerging biomarkers for MS management. Using examples from their own practice, the panelists also discuss ways to incorporate these biomarker findings into individualized treatment decisions to empower patients and improve treatment outcomes.

Upon completion of this activity, participants should be better able to:

  • Describe emerging biomarkers that may play a role in evaluating MS disease activity, progression, and treatment response
  • Individualize treatment decisions for patients with MS, incorporating biomarker findings, disease status, and other patient-specific characteristics
  • Integrate team-based shared decision-making strategies to facilitate appropriate treatment selection, empower patients, and improve outcomes

Target Audience

This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/CPE/IPCE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: June 3, 2023 - July 2, 2024
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.

Chair & Moderator
Jiwon Oh, MD, PhD, FRCPC
Medical Director, Barlo Multiple Sclerosis Program
Associate Professor, Division of Neurology
St. Michael’s Hospital
University of Toronto
Staff Neurologist
Scientist
Keenan Research Centre of the Li Ka Shing Knowledge Institute
Toronto, Ontario, Canada

Jiwon Oh, MD, PhD, FRCPC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; Bristol Myers Squibb; EMD Serono Canada; F. Hoffmann-La Roche Ltd; Lilly; Novartis Pharmaceuticals Canada Inc.; and Sanofi/Genzyme Canada Inc.
Grant/Research Support from Biogen Canada Inc.; EMD Serono Canada; and F. Hoffmann-La Roche Ltd.
Speaker for Biogen Canada Inc.; Bristol Myers Squibb; EMD Serono Canada; F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Canada Inc.; and Sanofi/Genzyme Canada Inc.

Presenters
Jacci Bainbridge, PharmD, FCCP, MSCS, FAES
Professor
Departments of Clinical Pharmacy and Neurology
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado, Anschutz Medical Campus
Aurora, Colorado

Jacci Bainbridge, PharmD, FCCP, MSCS, FAES, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Novartis Pharmaceuticals Corporation.

Kathleen M. Costello, RN, MS, NP, MSCN
Chief Operating Officer
Can Do-Multiple Sclerosis
Avon, Colorado

Kathleen M. Costello, RN, MS, NP, MSCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6939-23-T.

Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-039-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

June 02, 2023
Credits: 1.0 CME / NCPD / CPE
The National Lipid Association
Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents

Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents

Start

Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents

Activity Format: Internet Enduring Activity
Activity Release Date: June 2, 2023
Activity Expiration Date: July 1, 2024
Time to Complete Activity: 60 minutes

Program Overview

Elevated low-density lipoprotein cholesterol (LDL-C) levels are causally related to the risk of atherosclerotic cardiovascular disease (ASCVD)—justifying the guidance from multiple professional societies that emphasize the importance of lowering LDL-C to reduce cardiovascular risk. Despite the availability of nearly ten different classes of medications indicated to lower cholesterol levels, dyslipidemia is not appropriately managed for many patients, resulting in target LDL-C goals not being achieved. In this activity, based on a recent live symposium, experts discuss targeted therapies to optimize lipid management, including primary and secondary prevention of CV events, with PCSK9-targeting therapies (in particular, PCSK9 antibodies and novel small interfering RNAs).

Target Audience

This activity has been designed to meet the educational needs of cardiologists, internists, lipid specialists, nurses, pharmacists, and other clinicians involved in the management of hyperlipidemia.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Apply current hyperlipidemia treatment guidelines for primary and secondary prevention of cardiovascular events in patients with ASCVD
  • Assess the efficacy and safety data for PCSK9-targeting therapies for hyperlipidemia management in patients with ASCVD risk enhancers
  • Describe the mechanism of action and ability of PCSK9-targeting therapies to optimize treatment for high-risk ASCVD patients on maximally tolerated doses of statins or for statin-intolerant patients

Criteria for Success

Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme. The deadline to claim credit is July 1, 2024.

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

*IMPORTANT* Pharmacists MUST request credit before July 1, 2024. Credit requested after this date will be subject to a fee by the accreditation board.

Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Credit Designation

CME Credit Provided by the National Lipid Association

JAP In support of improving patient care, this activity has been planned and implemented by the National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physician Credit Designation Statement

The National Lipid Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CME Credit(s)TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistants

NCCPA accepts AMA PRA Category 1 CME CreditTM from organizations accredited by ACCME.

Pharmacists

This activity has been approved for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number – JA0007192-9999-23-007-H01-P (Knowledge).

Nursing

The maximum number of hours awarded for this CE activity is 1.0 contact hours.

For the advanced practice nurse, pharmacotherapy hours will be calculated on your certificate.

Faculty

Co-Chair & Presenter
P. Barton Duell, MD
Professor of Medicine
Director, Sterol Analysis Laboratory
Director, LDL Apheresis Unit
Oregon Health & Science University
Center for Preventive Cardiology
Knight Cardiovascular Institute
Division of Endocrinology, Diabetes and Clinical Nutrition
Portland, Oregon

P. Barton Duell, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Akcea Therapeutics, Inc./Ionis Pharmaceuticals; Esperion Therapeutics, Inc.; Kaneka Medical America LLC; Novo Nordisk Inc.; and Regeneron Pharmaceuticals Inc.
Grant/Research Support from Regeneron Pharmaceuticals Inc.; REGENXBIO Inc.; and Retrophin/Travere Therapeutics, Inc.

Co-Chair & Presenter
Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC
Clinical Pharmacist
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon

Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Akcea Pharmaceuticals.

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Disclosure of Unlabeled Use and Investigational Products

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure Declaration

It is the policy of the NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by the NLA prior to accreditation of the activity. The NLA planners and reviewers have no relevant financial relationships to disclose.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

Permissions

The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

Copyright © 2000-2023, PeerView

Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents

Activity Format: Internet Enduring Activity
Activity Release Date: June 2, 2023
Activity Expiration Date: July 1, 2024
Time to Complete Activity: 60 minutes

Program Overview

Elevated low-density lipoprotein cholesterol (LDL-C) levels are causally related to the risk of atherosclerotic cardiovascular disease (ASCVD)—justifying the guidance from multiple professional societies that emphasize the importance of lowering LDL-C to reduce cardiovascular risk. Despite the availability of nearly ten different classes of medications indicated to lower cholesterol levels, dyslipidemia is not appropriately managed for many patients, resulting in target LDL-C goals not being achieved. In this activity, based on a recent live symposium, experts discuss targeted therapies to optimize lipid management, including primary and secondary prevention of CV events, with PCSK9-targeting therapies (in particular, PCSK9 antibodies and novel small interfering RNAs).

Target Audience

This activity has been designed to meet the educational needs of cardiologists, internists, lipid specialists, nurses, pharmacists, and other clinicians involved in the management of hyperlipidemia.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Apply current hyperlipidemia treatment guidelines for primary and secondary prevention of cardiovascular events in patients with ASCVD
  • Assess the efficacy and safety data for PCSK9-targeting therapies for hyperlipidemia management in patients with ASCVD risk enhancers
  • Describe the mechanism of action and ability of PCSK9-targeting therapies to optimize treatment for high-risk ASCVD patients on maximally tolerated doses of statins or for statin-intolerant patients

Criteria for Success

Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme. The deadline to claim credit is July 1, 2024.

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

*IMPORTANT* Pharmacists MUST request credit before July 1, 2024. Credit requested after this date will be subject to a fee by the accreditation board.

Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Credit Designation

CME Credit Provided by the National Lipid Association

JAP In support of improving patient care, this activity has been planned and implemented by the National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physician Credit Designation Statement

The National Lipid Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CME Credit(s)TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistants

NCCPA accepts AMA PRA Category 1 CME CreditTM from organizations accredited by ACCME.

Pharmacists

This activity has been approved for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number – JA0007192-9999-23-007-H01-P (Knowledge).

Nursing

The maximum number of hours awarded for this CE activity is 1.0 contact hours.

For the advanced practice nurse, pharmacotherapy hours will be calculated on your certificate.

Faculty

Co-Chair & Presenter
P. Barton Duell, MD
Professor of Medicine
Director, Sterol Analysis Laboratory
Director, LDL Apheresis Unit
Oregon Health & Science University
Center for Preventive Cardiology
Knight Cardiovascular Institute
Division of Endocrinology, Diabetes and Clinical Nutrition
Portland, Oregon

P. Barton Duell, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Akcea Therapeutics, Inc./Ionis Pharmaceuticals; Esperion Therapeutics, Inc.; Kaneka Medical America LLC; Novo Nordisk Inc.; and Regeneron Pharmaceuticals Inc.
Grant/Research Support from Regeneron Pharmaceuticals Inc.; REGENXBIO Inc.; and Retrophin/Travere Therapeutics, Inc.

Co-Chair & Presenter
Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC
Clinical Pharmacist
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon

Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Akcea Pharmaceuticals.

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Disclosure of Unlabeled Use and Investigational Products

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure Declaration

It is the policy of the NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by the NLA prior to accreditation of the activity. The NLA planners and reviewers have no relevant financial relationships to disclose.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

Permissions

The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

Copyright © 2000-2023, PeerView

June 01, 2023
Credits: 1.0 CME / NCPD / CPE
PVI, PeerView Institute for Medical Education
Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition

Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition

Start

Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition

Media: Enduring Material
Activity Release Date: June 1, 2023
Activity Expiration Date: June 30, 2024
Time to Complete Activity: 60 minutes

Activity Description

Optimal management of multiple sclerosis (MS) requires selecting medications that safely and effectively target different aspects of pathophysiology and offer choices in administration, risk/benefit balance, and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an emerging class of disease-modifying therapies that affect processes mediated by B cells and myeloid cells, which are contributors to the inflammation and neurodegeneration that drive MS. BTK inhibitors are a novel class in MS management with four agents currently in phase 3 trials. As such, clinicians must remain up to date with the latest data on the rationale for their use and trial findings on the efficacy, safety, and tolerability of this promising line of treatment.

At a recent PeerView live event, MS experts shared relevant stories from their practice to highlight the rationale for the use of BTK inhibitors in MS, as well as perspectives on potential applications in clinical care and the latest data from clinical trials on BTK inhibition.

Target Audience

This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other clinicians involved in the care of patients with multiple sclerosis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Explain the rationale for investigating the potential of Bruton tyrosine kinase (BTK) inhibition in multiple sclerosis (MS) treatment
  • Assess emerging evidence on the risks and benefits associated with BTK inhibitors in late-stage clinical trials for the treatment of MS
  • Identify patients who might be candidates for treatment with a BTK inhibitor, based on available data as well as individual patient characteristics and priorities

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Amit Bar-Or, MD, FRCPC
Melissa and Paul Anderson President’s Distinguished Chair
Professor, Department of Neurology
Chief, Division of Multiple Sclerosis and Related Disorders
Director, Centre for Neuroinflammation and Experimental Therapeutics
University of Pennsylvania
Children’s Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania

Amit Bar-Or, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Accure Pharma; Atara Biotherapeutics, Inc.; Biogen; Bristol Myers Squibb/Celgene Corporation/Receptos, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Gossamer Bio; Janssen Pharmaceuticals, Inc./Actelion Pharmaceuticals US, Inc.; Medimmune, LLC; Merck & Co., Inc./EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; and Sanofi Genzyme.
Grant/Research Support from Biogen; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Merck & Co., Inc./EMD Serono, Inc.; and Novartis Pharmaceuticals Corporation (paid to institution).

Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada

Professor Anthony Traboulsee, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; F. Hoffmann-La Roche Ltd; Genzyme Corporation; and Novartis Pharmaceuticals Canada Inc.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Genzyme Corporation.
Speaker for F. Hoffmann-La Roche Ltd and Genzyme Corporation.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-014-H01-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition

Media: Enduring Material
Activity Release Date: June 1, 2023
Activity Expiration Date: June 30, 2024
Time to Complete Activity: 60 minutes

Activity Description

Optimal management of multiple sclerosis (MS) requires selecting medications that safely and effectively target different aspects of pathophysiology and offer choices in administration, risk/benefit balance, and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an emerging class of disease-modifying therapies that affect processes mediated by B cells and myeloid cells, which are contributors to the inflammation and neurodegeneration that drive MS. BTK inhibitors are a novel class in MS management with four agents currently in phase 3 trials. As such, clinicians must remain up to date with the latest data on the rationale for their use and trial findings on the efficacy, safety, and tolerability of this promising line of treatment.

At a recent PeerView live event, MS experts shared relevant stories from their practice to highlight the rationale for the use of BTK inhibitors in MS, as well as perspectives on potential applications in clinical care and the latest data from clinical trials on BTK inhibition.

Target Audience

This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other clinicians involved in the care of patients with multiple sclerosis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Explain the rationale for investigating the potential of Bruton tyrosine kinase (BTK) inhibition in multiple sclerosis (MS) treatment
  • Assess emerging evidence on the risks and benefits associated with BTK inhibitors in late-stage clinical trials for the treatment of MS
  • Identify patients who might be candidates for treatment with a BTK inhibitor, based on available data as well as individual patient characteristics and priorities

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Amit Bar-Or, MD, FRCPC
Melissa and Paul Anderson President’s Distinguished Chair
Professor, Department of Neurology
Chief, Division of Multiple Sclerosis and Related Disorders
Director, Centre for Neuroinflammation and Experimental Therapeutics
University of Pennsylvania
Children’s Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania

Amit Bar-Or, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Accure Pharma; Atara Biotherapeutics, Inc.; Biogen; Bristol Myers Squibb/Celgene Corporation/Receptos, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Gossamer Bio; Janssen Pharmaceuticals, Inc./Actelion Pharmaceuticals US, Inc.; Medimmune, LLC; Merck & Co., Inc./EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; and Sanofi Genzyme.
Grant/Research Support from Biogen; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Merck & Co., Inc./EMD Serono, Inc.; and Novartis Pharmaceuticals Corporation (paid to institution).

Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada

Professor Anthony Traboulsee, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; F. Hoffmann-La Roche Ltd; Genzyme Corporation; and Novartis Pharmaceuticals Canada Inc.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Genzyme Corporation.
Speaker for F. Hoffmann-La Roche Ltd and Genzyme Corporation.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-014-H01-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

May 31, 2023
Patrick A. Flume, MD/Gwen A. Huitt, MD, MS
Credits: 0.5 CME / MOC / NCPD / CPE / IPCE
PVI, PeerView Institute for Medical Education
Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management

Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management

Start

Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management

Media: Enduring Material
Activity Release Date: May 19, 2023
Activity Expiration Date: May 18, 2024
Time to Complete Activity: 30 minutes

Activity Description

In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life.

Target Audience

This activity has been designed to meet the educational needs of infectious disease specialists, respirologists, pulmonologists, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the management of patients with NTM-LD.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis
  • Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care
  • Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Patrick A. Flume, MD
Distinguished Professor of Medicine and Pediatrics
Medical University of South Carolina
Charleston, South Carolina

Patrick A. Flume, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Aceragen Inc.; Chiesi USA, Inc.; Eloxx Pharmaceuticals, Inc.; Insmed Incorporated; Ionis Pharmaceuticals; Janssen Pharmaceuticals, Inc.; McKesson Corporation; Merck & Co., Inc.; Polyphor; Santhera Pharmaceuticals; and Vertex Pharmaceuticals Incorporated.
Grant/Research Support from AbbVie Inc.; Aceragen Inc.; Armata Pharmaceuticals, Inc.; AstraZeneca; Insmed Incorporated; Janssen Pharmaceuticals, Inc.; Novovax; RedHill Biopharma Ltd; Sound Pharmaceuticals; and Vertex Pharmaceuticals Incorporated.

Co-Chair/Planner
Gwen A. Huitt, MD, MS
Professor, National Jewish Health (Ret.)
Division of Mycobacterial and Respiratory Infections
Denver, Colorado

Gwen A. Huitt, MD, MS, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Susan Palmer

Susan Palmer has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Insmed.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-042-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management

Media: Enduring Material
Activity Release Date: May 19, 2023
Activity Expiration Date: May 18, 2024
Time to Complete Activity: 30 minutes

Activity Description

In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life.

Target Audience

This activity has been designed to meet the educational needs of infectious disease specialists, respirologists, pulmonologists, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the management of patients with NTM-LD.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis
  • Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care
  • Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Patrick A. Flume, MD
Distinguished Professor of Medicine and Pediatrics
Medical University of South Carolina
Charleston, South Carolina

Patrick A. Flume, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Aceragen Inc.; Chiesi USA, Inc.; Eloxx Pharmaceuticals, Inc.; Insmed Incorporated; Ionis Pharmaceuticals; Janssen Pharmaceuticals, Inc.; McKesson Corporation; Merck & Co., Inc.; Polyphor; Santhera Pharmaceuticals; and Vertex Pharmaceuticals Incorporated.
Grant/Research Support from AbbVie Inc.; Aceragen Inc.; Armata Pharmaceuticals, Inc.; AstraZeneca; Insmed Incorporated; Janssen Pharmaceuticals, Inc.; Novovax; RedHill Biopharma Ltd; Sound Pharmaceuticals; and Vertex Pharmaceuticals Incorporated.

Co-Chair/Planner
Gwen A. Huitt, MD, MS
Professor, National Jewish Health (Ret.)
Division of Mycobacterial and Respiratory Infections
Denver, Colorado

Gwen A. Huitt, MD, MS, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Susan Palmer

Susan Palmer has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Insmed.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-042-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

May 18, 2023
Credits: 1.0 CME / NCPD / CPE / IPCE
PVI, PeerView Institute for Medical Education
Leveraging FcRn Modulation in Personalized Management of Generalized Myasthenia Gravis: Applying the Evidence, Tools, and Patient Perspectives to Achieve Treatment Goals

Leveraging FcRn Modulation in Personalized Management of Generalized Myasthenia Gravis: Applying the Evidence, Tools, and Patient Perspectives to Achieve Treatment Goals

Start

Leveraging FcRn Modulation in Personalized Management of Generalized Myasthenia Gravis: Applying the Evidence, Tools, and Patient Perspectives to Achieve Treatment Goals

Media: Enduring Material
Activity Release Date: May 11, 2023
Activity Expiration Date: May 10, 2024
Time to Complete Activity: 60 minutes

Activity Description

An international panel of experts discusses the data on clinical outcomes, safety, and efficacy of new and emerging therapies for the treatment of myasthenia gravis. The interdisciplinary discussion focuses on FcRn modulation and personalized treatment approaches, and includes an interview with a patient who discusses her life and treatment journey with myasthenia gravis.

Target Audience

This activity has been designed to meet the educational needs of US and EU neurologists, including neuromuscular and neuroimmunology specialists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the care of patients with gMG.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Integrate new and emerging gMG-targeted therapies into treatment plans as appropriate, based on an understanding of the data on clinical outcomes, safety, and effects on quality of life
  • Develop a management strategy that incorporates the patient’s perspective in identifying treatment goals and choices
  • Implement a safe, individualized administration protocol for the management of gMG that responds to clinical and patient-reported outcomes measures of treatment response and adverse events

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Vera Bril, BSc, FRCPC, MD
Professor of Medicine
Director of the Neuromuscular Section
Division of Neurology
University of Toronto
University Health Network
Toronto, Ontario, Canada

Vera Bril, BSc, FRCPC, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Akcea Therapeutics, Inc.; Alnylam Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals, Inc.; CSL Behring; F. Hoffmann-La Roche Ltd; Ionis Pharmaceuticals; Immunovant, Inc.; Janssen Inc.; Momenta Pharmaceuticals, Inc./Johnson & Johnson Services, Inc.; Novo Nordisk Inc.; Octapharma Canada Inc.; Powell Mansfield Inc.; Pfizer; Sanofi; Takeda Pharmaceutical Company; and UCB Canada Inc.
Grant/Research Support from Akcea Therapeutics, Inc.; Alnylam Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals, Inc.; CSL Behring; Ionis Pharmaceuticals; Momenta Pharmaceuticals, Inc./Johnson & Johnson Services; Octapharma Canada Inc.; Takeda Pharmaceutical Company; and UCB Canada Inc.
Speaker for Akcea Therapeutics, Inc.; Alnylam Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals, Inc.; and CSL Behring.

Faculty/Planner
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing Practice
Optum Infusion Pharmacy
Lenexa, Kansas

Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion S.p.A; Koru Pharmaceuticals Co., LTD.; Octapharma USA, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty/Planner
Francesco Saccà, MD
Associate Professor of Neurology
NSRO Department
University "Federico II"
Naples, Italy

Francesco Saccà, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; argenx; Lexeo Therapeutics, Inc.; Novartis AG; Reata Pharmaceuticals, Inc.; and Takeda Italia S.p.A.
Speaker for Alexion Pharmaceuticals, Inc. and Novartis AG.

Patient/Planner
Kaitlin Stockwell Masters

Kaitlin Stockwell Masters has a financial interest/relationship or affiliation in the form of:
Speaker for argenx.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from argenx US, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-040-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Leveraging FcRn Modulation in Personalized Management of Generalized Myasthenia Gravis: Applying the Evidence, Tools, and Patient Perspectives to Achieve Treatment Goals

Media: Enduring Material
Activity Release Date: May 11, 2023
Activity Expiration Date: May 10, 2024
Time to Complete Activity: 60 minutes

Activity Description

An international panel of experts discusses the data on clinical outcomes, safety, and efficacy of new and emerging therapies for the treatment of myasthenia gravis. The interdisciplinary discussion focuses on FcRn modulation and personalized treatment approaches, and includes an interview with a patient who discusses her life and treatment journey with myasthenia gravis.

Target Audience

This activity has been designed to meet the educational needs of US and EU neurologists, including neuromuscular and neuroimmunology specialists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the care of patients with gMG.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Integrate new and emerging gMG-targeted therapies into treatment plans as appropriate, based on an understanding of the data on clinical outcomes, safety, and effects on quality of life
  • Develop a management strategy that incorporates the patient’s perspective in identifying treatment goals and choices
  • Implement a safe, individualized administration protocol for the management of gMG that responds to clinical and patient-reported outcomes measures of treatment response and adverse events

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Vera Bril, BSc, FRCPC, MD
Professor of Medicine
Director of the Neuromuscular Section
Division of Neurology
University of Toronto
University Health Network
Toronto, Ontario, Canada

Vera Bril, BSc, FRCPC, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Akcea Therapeutics, Inc.; Alnylam Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals, Inc.; CSL Behring; F. Hoffmann-La Roche Ltd; Ionis Pharmaceuticals; Immunovant, Inc.; Janssen Inc.; Momenta Pharmaceuticals, Inc./Johnson & Johnson Services, Inc.; Novo Nordisk Inc.; Octapharma Canada Inc.; Powell Mansfield Inc.; Pfizer; Sanofi; Takeda Pharmaceutical Company; and UCB Canada Inc.
Grant/Research Support from Akcea Therapeutics, Inc.; Alnylam Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals, Inc.; CSL Behring; Ionis Pharmaceuticals; Momenta Pharmaceuticals, Inc./Johnson & Johnson Services; Octapharma Canada Inc.; Takeda Pharmaceutical Company; and UCB Canada Inc.
Speaker for Akcea Therapeutics, Inc.; Alnylam Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals, Inc.; and CSL Behring.

Faculty/Planner
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing Practice
Optum Infusion Pharmacy
Lenexa, Kansas

Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion S.p.A; Koru Pharmaceuticals Co., LTD.; Octapharma USA, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty/Planner
Francesco Saccà, MD
Associate Professor of Neurology
NSRO Department
University "Federico II"
Naples, Italy

Francesco Saccà, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; argenx; Lexeo Therapeutics, Inc.; Novartis AG; Reata Pharmaceuticals, Inc.; and Takeda Italia S.p.A.
Speaker for Alexion Pharmaceuticals, Inc. and Novartis AG.

Patient/Planner
Kaitlin Stockwell Masters

Kaitlin Stockwell Masters has a financial interest/relationship or affiliation in the form of:
Speaker for argenx.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from argenx US, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-040-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

May 10, 2023
Anna Chodos, MD, MPH/Ian Neel, MD
Credits: 1.0 CME / MOC / NCPD / CPE / APA / IPCE
PVI, PeerView Institute for Medical Education
Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care

Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care

Start

Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care

Media: Enduring Material
Activity Release Date: April 26, 2023
Activity Expiration Date: May 25, 2024
Time to Complete Activity: 60 minutes

Activity Description

The timely detection and diagnosis of Alzheimer’s disease (AD) can provide patients with numerous opportunities—earlier treatment initiation, increased eligibility for clinical trials, participation in long-term care planning, and the chance to make lifestyle changes to slow cognitive decline. In this activity, based on a recent live symposium, experts discuss practical strategies for integrating cognitive screening into routine care visits and conducting more detailed cognitive evaluations that results in a written care plan with patients who fail a brief cognitive screening assessment. Experts also share guidance on working with Medicare reimbursement mechanisms to facilitate consistent and effective use of early detection tools and practical skills to counsel patients and their caregivers before, during, and after the diagnostic process.

Target Audience

This activity has been designed to meet the educational needs of internal medicine physicians, family medicine physicians, geriatricians, advanced practice clinicians, nurses, pharmacists, psychologists, and other clinicians involved in the assessment and care of patients with or at risk for Alzheimer's disease.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Integrate routine cognitive assessment in outpatient visits of older adults who present with signs and symptoms of cognitive impairment to facilitate the timely diagnosis of MCI and mild dementia due to AD
  • Employ appropriate tools for documentation and coding of procedures (eg, cognitive assessments) and services for patients presenting with cognitive symptoms or concerns
  • Implement effective communication strategies to educate patients and caregivers about the clinical significance and prognostic implications of their cognitive assessment results

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Anna Chodos, MD, MPH
Associate Professor of Medicine
Division of Geriatrics and Division of General Internal Medicine
Zuckerberg San Francisco General Hospital
Department of Medicine
University of California
San Francisco, California

Anna Chodos, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
Ian Neel, MD
Associate Clinical Professor of Medicine
Medical Director, Geriatric Medicine Consult Service
Senior Behavioral Health
UC San Diego Medical Center
San Diego, California

Ian Neel, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Centene Corporation/Health Net Pharmacy and Therapeutics Committee.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-022-H01-P
Type of Activity: Application

Psychologists

APA Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/APA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care

Media: Enduring Material
Activity Release Date: April 26, 2023
Activity Expiration Date: May 25, 2024
Time to Complete Activity: 60 minutes

Activity Description

The timely detection and diagnosis of Alzheimer’s disease (AD) can provide patients with numerous opportunities—earlier treatment initiation, increased eligibility for clinical trials, participation in long-term care planning, and the chance to make lifestyle changes to slow cognitive decline. In this activity, based on a recent live symposium, experts discuss practical strategies for integrating cognitive screening into routine care visits and conducting more detailed cognitive evaluations that results in a written care plan with patients who fail a brief cognitive screening assessment. Experts also share guidance on working with Medicare reimbursement mechanisms to facilitate consistent and effective use of early detection tools and practical skills to counsel patients and their caregivers before, during, and after the diagnostic process.

Target Audience

This activity has been designed to meet the educational needs of internal medicine physicians, family medicine physicians, geriatricians, advanced practice clinicians, nurses, pharmacists, psychologists, and other clinicians involved in the assessment and care of patients with or at risk for Alzheimer's disease.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Integrate routine cognitive assessment in outpatient visits of older adults who present with signs and symptoms of cognitive impairment to facilitate the timely diagnosis of MCI and mild dementia due to AD
  • Employ appropriate tools for documentation and coding of procedures (eg, cognitive assessments) and services for patients presenting with cognitive symptoms or concerns
  • Implement effective communication strategies to educate patients and caregivers about the clinical significance and prognostic implications of their cognitive assessment results

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Anna Chodos, MD, MPH
Associate Professor of Medicine
Division of Geriatrics and Division of General Internal Medicine
Zuckerberg San Francisco General Hospital
Department of Medicine
University of California
San Francisco, California

Anna Chodos, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
Ian Neel, MD
Associate Clinical Professor of Medicine
Medical Director, Geriatric Medicine Consult Service
Senior Behavioral Health
UC San Diego Medical Center
San Diego, California

Ian Neel, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Centene Corporation/Health Net Pharmacy and Therapeutics Committee.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-022-H01-P
Type of Activity: Application

Psychologists

APA Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/APA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

April 25, 2023
Credits: 1.0 CPE
PVI, PeerView Institute for Medical Education
Coordinating Better Outcomes in Multiple Myeloma: Pharmacist Leadership With Novel Antibodies and CAR-T Therapy

Coordinating Better Outcomes in Multiple Myeloma: Pharmacist Leadership With Novel Antibodies and CAR-T Therapy

Start

Coordinating Better Outcomes in Multiple Myeloma: Pharmacist Leadership With Novel Antibodies and CAR-T Therapy

Media: Enduring Material
Activity Release Date: April 14, 2023
Activity Expiration Date: May 13, 2024
Time to Complete Activity: 60 minutes

Activity Description

Find out if you are prepared to integrate cutting-edge antibody and CAR-T options for the care of patients with multiple myeloma (MM). In this PeerView Pharmacy MasterClass and Case Forum activity, an expert panel will offer guidance on how pharmacists can tackle the real-world challenges of MM management by facilitating care with CD38 and BCMA-directed antibodies, as well as CAR-T therapy, in a range of different treatment settings. Our experts will provide insights into how pharmacists can help modernize MM treatment protocols by ensuring appropriate care coordination and addressing safety, dosing, and therapy delivery considerations associated with CD38 and BCMA-directed treatment. Participate in this CPE video activity to see if you are prepared to lead the way to better outcomes for MM!

Target Audience

This activity has been designed to meet the educational needs of hematology-oncology pharmacists, pharmacy managers, and other healthcare professionals involved in the management of multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the mechanisms of action, dosing, efficacy evidence, and safety evidence supporting the treatment roles of antibody-based and CAR-T therapies in multiple myeloma (MM), including CD38 and BCMA-directed agents
  • Implement pharmacist-guided strategies to promote optimal clinical integration of established and emerging antibody and cellular therapies across the spectrum of MM
  • Develop modernized patient-, staff-, and institution-directed protocols to address practical aspects of care when using antibody and cellular therapy platforms, including dosing, safety, patient and staff counseling, and managing supportive therapies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Professor, Hematology/Medical Oncology and Pharmacology and Chemical Biology
Emory University School of Medicine
Medical Director, Clinical Trials Office
Director, Phase I Clinical Trials Section
Winship Cancer Institute of Emory University
Atlanta, Georgia

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen and GlaxoSmithKline.
Grant/Research Support from Abbisko Therapeutics; AbbVie; Actuate Therapeutics, Inc.; Amgen; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Genmab A/S; GlaxoSmithKline; Infinity Pharmaceuticals, Inc.; Inhibrx, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Mersana Therapeutics; Meryx; MorphoSys; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; Sutro Biopharma, Inc.; Takeda Pharmaceutical Company Limited; Turning Point Therapeutics, Inc. and Xencor, Inc. Research funding to institution.

Co-Chair/Planner
Zahra Mahmoudjafari, PharmD, MBA, BCOP
Clinical Pharmacy Manager, Blood and Marrow Transplant Program
Division of Hematologic Malignancies and Cellular Therapeutics
PGY2 Oncology Residency Program Director
The University of Kansas Cancer Center
Kansas City, Kansas

Zahra Mahmoudjafari, PharmD, MBA, BCOP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Incyte Corporation; Kite Pharma; Merck & Co., Inc.; Omeros Corporation; Sanofi; and Seagen Inc.
Speaker for Omeros Corporation.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. and Sanofi.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-036-H01-P
Type of Activity: Application

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Coordinating Better Outcomes in Multiple Myeloma: Pharmacist Leadership With Novel Antibodies and CAR-T Therapy

Media: Enduring Material
Activity Release Date: April 14, 2023
Activity Expiration Date: May 13, 2024
Time to Complete Activity: 60 minutes

Activity Description

Find out if you are prepared to integrate cutting-edge antibody and CAR-T options for the care of patients with multiple myeloma (MM). In this PeerView Pharmacy MasterClass and Case Forum activity, an expert panel will offer guidance on how pharmacists can tackle the real-world challenges of MM management by facilitating care with CD38 and BCMA-directed antibodies, as well as CAR-T therapy, in a range of different treatment settings. Our experts will provide insights into how pharmacists can help modernize MM treatment protocols by ensuring appropriate care coordination and addressing safety, dosing, and therapy delivery considerations associated with CD38 and BCMA-directed treatment. Participate in this CPE video activity to see if you are prepared to lead the way to better outcomes for MM!

Target Audience

This activity has been designed to meet the educational needs of hematology-oncology pharmacists, pharmacy managers, and other healthcare professionals involved in the management of multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the mechanisms of action, dosing, efficacy evidence, and safety evidence supporting the treatment roles of antibody-based and CAR-T therapies in multiple myeloma (MM), including CD38 and BCMA-directed agents
  • Implement pharmacist-guided strategies to promote optimal clinical integration of established and emerging antibody and cellular therapies across the spectrum of MM
  • Develop modernized patient-, staff-, and institution-directed protocols to address practical aspects of care when using antibody and cellular therapy platforms, including dosing, safety, patient and staff counseling, and managing supportive therapies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Professor, Hematology/Medical Oncology and Pharmacology and Chemical Biology
Emory University School of Medicine
Medical Director, Clinical Trials Office
Director, Phase I Clinical Trials Section
Winship Cancer Institute of Emory University
Atlanta, Georgia

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen and GlaxoSmithKline.
Grant/Research Support from Abbisko Therapeutics; AbbVie; Actuate Therapeutics, Inc.; Amgen; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Genmab A/S; GlaxoSmithKline; Infinity Pharmaceuticals, Inc.; Inhibrx, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Mersana Therapeutics; Meryx; MorphoSys; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; Sutro Biopharma, Inc.; Takeda Pharmaceutical Company Limited; Turning Point Therapeutics, Inc. and Xencor, Inc. Research funding to institution.

Co-Chair/Planner
Zahra Mahmoudjafari, PharmD, MBA, BCOP
Clinical Pharmacy Manager, Blood and Marrow Transplant Program
Division of Hematologic Malignancies and Cellular Therapeutics
PGY2 Oncology Residency Program Director
The University of Kansas Cancer Center
Kansas City, Kansas

Zahra Mahmoudjafari, PharmD, MBA, BCOP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Incyte Corporation; Kite Pharma; Merck & Co., Inc.; Omeros Corporation; Sanofi; and Seagen Inc.
Speaker for Omeros Corporation.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. and Sanofi.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-036-H01-P
Type of Activity: Application

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

April 13, 2023
Credits: 1.0 CME / MOC / NCPD / CPE
PVI, PeerView Institute for Medical Education
Critical Conversations on Atrial Fibrillation: A MasterClass Series

Critical Conversations on Atrial Fibrillation: A MasterClass Series

Start

Critical Conversations on Atrial Fibrillation: A MasterClass Series

Activity Description and Educational Objectives

Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF.

Upon completion of this activity, participants should be better able to:

  • Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society
  • Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology
  • Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics

Target Audience

This activity has been designed to meet the educational needs of family medicine and internal medicine physicians, nurse practitioners, physician assistants, pharmacists, nurses, and other clinicians involved in the care of patients with or at risk for AF.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: April 4, 2023 - April 3, 2024
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.

Co-Chairs & Presenters
Sean Pokorney, MD, MBA
Assistant Professor of Medicine
Director of the Arrhythmia Core Laboratory
Duke Clinical Research Institute
Duke University
Raleigh, North Carolina

Sean Pokorney, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Boston Scientific Corporation; Bristol Myers Squibb; Medtronic; Pfizer; and Phillips Healthcare Corporation.
Grant/Research Support from Boston Scientific Corporation; Bristol Myers Squibb; Medtronic; Pfizer; and Phillips Healthcare Corporation.
Speakers Bureau participant with Boston Scientific Corporation; Medtronic; Phillips Healthcare Corporation; Sanofi; and Zoll.

Emily P. Zeitler, MD, MHS, FACC, FHRS
Clinical Electrophysiology
Dartmouth Health
Assistant Professor of Medicine
Geisel School of Medicine
Assistant Professor of Health Care Policy
The Dartmouth Institute
Lebanon, New Hampshire

Emily P. Zeitler, MD, MHS, FACC, FHRS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; Biosense Webster Inc.; and Medtronic.
Grant/Research Support from Biosense Webster Inc. (Johnson & Johnson Services, Inc.); Boston Scientific Corporation; and Sanofi.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6923-23-T.

Support

This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-030-H01-P
Type of Activity: Knowledge

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Critical Conversations on Atrial Fibrillation: A MasterClass Series

Activity Description and Educational Objectives

Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF.

Upon completion of this activity, participants should be better able to:

  • Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society
  • Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology
  • Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics

Target Audience

This activity has been designed to meet the educational needs of family medicine and internal medicine physicians, nurse practitioners, physician assistants, pharmacists, nurses, and other clinicians involved in the care of patients with or at risk for AF.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: April 4, 2023 - April 3, 2024
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.

Co-Chairs & Presenters
Sean Pokorney, MD, MBA
Assistant Professor of Medicine
Director of the Arrhythmia Core Laboratory
Duke Clinical Research Institute
Duke University
Raleigh, North Carolina

Sean Pokorney, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Boston Scientific Corporation; Bristol Myers Squibb; Medtronic; Pfizer; and Phillips Healthcare Corporation.
Grant/Research Support from Boston Scientific Corporation; Bristol Myers Squibb; Medtronic; Pfizer; and Phillips Healthcare Corporation.
Speakers Bureau participant with Boston Scientific Corporation; Medtronic; Phillips Healthcare Corporation; Sanofi; and Zoll.

Emily P. Zeitler, MD, MHS, FACC, FHRS
Clinical Electrophysiology
Dartmouth Health
Assistant Professor of Medicine
Geisel School of Medicine
Assistant Professor of Health Care Policy
The Dartmouth Institute
Lebanon, New Hampshire

Emily P. Zeitler, MD, MHS, FACC, FHRS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; Biosense Webster Inc.; and Medtronic.
Grant/Research Support from Biosense Webster Inc. (Johnson & Johnson Services, Inc.); Boston Scientific Corporation; and Sanofi.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6923-23-T.

Support

This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-030-H01-P
Type of Activity: Knowledge

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

April 03, 2023
Credits: 1.0 CME / MOC / CPE / IPCE
PVI, PeerView Institute for Medical Education
Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy

Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy

Start

Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy

Media: Enduring Material
Activity Release Date: March 31, 2023
Activity Expiration Date: April 29, 2024
Time to Complete Activity: 60 minutes

Activity Description

Are you prepared to implement advances with targeted agents in CLL in your pharmacy practice? Find out by viewing this “Pharmacy MasterClass & Case Forum” program, recorded during the 2023 Hematology/Oncology Pharmacy Association (HOPA) 19th Annual Conference. Throughout, expert pharmacists will present state-of-the-art evidence supporting the use of highly efficacious targeted strategies in CLL, including covalent and non-covalent BTK inhibitors, BCL2 inhibitors, and chemo-sparing combinations, and give insights on how to apply the evidence supporting these strategies to real-world practice. The experts will also prepare you to anticipate and manage adverse events; proactively address drug interaction and dosing complexities; and provide staff and patient education on single-agent and combination strategies. Don’t miss this opportunity to get the latest on the new treatment mix in CLL!

Target Audience

This activity has been designed to meet the educational needs of hematology-oncology pharmacists, pharmacy managers, and other clinicians involved in the management of CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the mechanistic and pharmacokinetic profiles, and safety/efficacy evidence supporting the treatment roles of novel BTK and BCL-2 inhibitor approaches in CLL
  • Develop pharmacy-guided plans to optimize the integration of novel and emerging BTK and BCL-2 inhibitor strategies into personalized management plans for patients with TN and RR CLL
  • Work collaboratively to address practical aspects of team-based care with targeted therapies in CLL, including care coordination, drug-drug interactions, patient counseling, staff education, and safety and dosing considerations

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Emily K. Dotson, PharmD, BCOP
Inpatient Clinical Manager
Clinical Pharmacist Specialist - Hematology
The James Cancer Hospital
Columbus, Ohio

Emily K. Dotson, PharmD, BCOP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; BeiGene; and Janssen Pharmaceuticals, Inc.

Faculty/Planner
Peter Campbell, PharmD, MBA, BCOP
Clinical Pharmacy Manager Lead
NewYork-Presbyterian Hospital, Columbia University Irving Medical Center
Program Director, PGY2 Oncology Pharmacy Residency
NewYork-Presbyterian Hospital
New York, New York

Peter Campbell, PharmD, MBA, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Sarah E. Stump, PharmD, BCPS, BCOP
Clinical Pharmacy Specialist – Adult Malignant Hematology
Vanderbilt University Medical Center
Nashville, Tennessee

Sarah E. Stump, PharmD, BCPS, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-012-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy

Media: Enduring Material
Activity Release Date: March 31, 2023
Activity Expiration Date: April 29, 2024
Time to Complete Activity: 60 minutes

Activity Description

Are you prepared to implement advances with targeted agents in CLL in your pharmacy practice? Find out by viewing this “Pharmacy MasterClass & Case Forum” program, recorded during the 2023 Hematology/Oncology Pharmacy Association (HOPA) 19th Annual Conference. Throughout, expert pharmacists will present state-of-the-art evidence supporting the use of highly efficacious targeted strategies in CLL, including covalent and non-covalent BTK inhibitors, BCL2 inhibitors, and chemo-sparing combinations, and give insights on how to apply the evidence supporting these strategies to real-world practice. The experts will also prepare you to anticipate and manage adverse events; proactively address drug interaction and dosing complexities; and provide staff and patient education on single-agent and combination strategies. Don’t miss this opportunity to get the latest on the new treatment mix in CLL!

Target Audience

This activity has been designed to meet the educational needs of hematology-oncology pharmacists, pharmacy managers, and other clinicians involved in the management of CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the mechanistic and pharmacokinetic profiles, and safety/efficacy evidence supporting the treatment roles of novel BTK and BCL-2 inhibitor approaches in CLL
  • Develop pharmacy-guided plans to optimize the integration of novel and emerging BTK and BCL-2 inhibitor strategies into personalized management plans for patients with TN and RR CLL
  • Work collaboratively to address practical aspects of team-based care with targeted therapies in CLL, including care coordination, drug-drug interactions, patient counseling, staff education, and safety and dosing considerations

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Emily K. Dotson, PharmD, BCOP
Inpatient Clinical Manager
Clinical Pharmacist Specialist - Hematology
The James Cancer Hospital
Columbus, Ohio

Emily K. Dotson, PharmD, BCOP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; BeiGene; and Janssen Pharmaceuticals, Inc.

Faculty/Planner
Peter Campbell, PharmD, MBA, BCOP
Clinical Pharmacy Manager Lead
NewYork-Presbyterian Hospital, Columbia University Irving Medical Center
Program Director, PGY2 Oncology Pharmacy Residency
NewYork-Presbyterian Hospital
New York, New York

Peter Campbell, PharmD, MBA, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Sarah E. Stump, PharmD, BCPS, BCOP
Clinical Pharmacy Specialist – Adult Malignant Hematology
Vanderbilt University Medical Center
Nashville, Tennessee

Sarah E. Stump, PharmD, BCPS, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-012-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

March 30, 2023

Pages